Literature DB >> 25143264

Cytosolic DNA sensing via the stimulator of interferon genes adaptor: Yin and Yang of immune responses to DNA.

Henrique Lemos1, Lei Huang, Tracy L McGaha, Andrew L Mellor.   

Abstract

DNA is immunogenic and many cells express cytosolic DNA sensors that activate the stimulator of interferon genes (STING) adaptor to trigger interferon type I (IFN-β) release, a potent immune activator. DNA sensing to induce IFN-β triggers host immunity to pathogens but constitutive DNA sensing can induce sustained IFN-β release that incites autoimmunity. Here, we focus on cytosolic DNA sensing via the STING/IFN-β pathway that regulates immune responses. Recent studies reveal that cytosolic DNA sensing via the STING/IFN-β pathway induces indoleamine 2,3 dioxygenase (IDO), which catabolizes tryptophan to suppress effector and helper T-cell responses and activate Foxp3-lineage CD4(+) regulatory T (Treg) cells. During homeostasis, and in some inflammatory settings, specialized innate immune cells in the spleen and lymph nodes may ingest and sense cytosolic DNA to reinforce tolerance that prevents autoimmunity. However, malignancies and pathogens may exploit DNA-induced regulatory responses to suppress natural and vaccine-induced immunity to malignant and infected cells. In this review, we discuss the biologic significance of regulatory responses to DNA and novel approaches to exploit DNA-induced immune responses for therapeutic benefit. The ability of DNA to drive tolerogenic or immunogenic responses highlights the need to evaluate immune responses to DNA in physiologic settings relevant to disease progression or therapy.
© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Autoimmunity; DNA sensors; STING; Tolerance; Type I Interferon

Mesh:

Substances:

Year:  2014        PMID: 25143264      PMCID: PMC4197080          DOI: 10.1002/eji.201344407

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  49 in total

1.  Autoimmunity initiates in nonhematopoietic cells and progresses via lymphocytes in an interferon-dependent autoimmune disease.

Authors:  Alevtina Gall; Piper Treuting; Keith B Elkon; Yueh-Ming Loo; Michael Gale; Glen N Barber; Daniel B Stetson
Journal:  Immunity       Date:  2012-01-27       Impact factor: 31.745

2.  Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO.

Authors:  Gerhard Wingender; Natalio Garbi; Beatrix Schumak; Frank Jüngerkes; Elmar Endl; Dagmar von Bubnoff; Julia Steitz; Jörg Striegler; Gerd Moldenhauer; Thomas Tüting; Antje Heit; Katharina M Huster; Osamu Takikawa; Shizuo Akira; Dirk H Busch; Hermann Wagner; Günter J Hämmerling; Percy A Knolle; Andreas Limmer
Journal:  Eur J Immunol       Date:  2006-01       Impact factor: 5.532

3.  Physiologic control of IDO competence in splenic dendritic cells.

Authors:  Babak Baban; Phillip R Chandler; Burles A Johnson; Lei Huang; Minghui Li; Marlon L Sharpe; Loise M Francisco; Arlene H Sharpe; Bruce R Blazar; David H Munn; Andrew L Mellor
Journal:  J Immunol       Date:  2011-08-03       Impact factor: 5.422

4.  Persistent LCMV infection is controlled by blockade of type I interferon signaling.

Authors:  John R Teijaro; Cherie Ng; Andrew M Lee; Brian M Sullivan; Kathleen C F Sheehan; Megan Welch; Robert D Schreiber; Juan Carlos de la Torre; Michael B A Oldstone
Journal:  Science       Date:  2013-04-12       Impact factor: 47.728

Review 5.  The cGAS-STING pathway for DNA sensing.

Authors:  T Sam Xiao; Katherine A Fitzgerald
Journal:  Mol Cell       Date:  2013-07-25       Impact factor: 17.970

6.  Cutting edge: DNA sensing via the STING adaptor in myeloid dendritic cells induces potent tolerogenic responses.

Authors:  Lei Huang; Lingqian Li; Henrique Lemos; Phillip R Chandler; Gabriela Pacholczyk; Babak Baban; Glen N Barber; Yoshihiro Hayakawa; Tracy L McGaha; Buvana Ravishankar; David H Munn; Andrew L Mellor
Journal:  J Immunol       Date:  2013-08-28       Impact factor: 5.422

7.  Histo-cytometry: a method for highly multiplex quantitative tissue imaging analysis applied to dendritic cell subset microanatomy in lymph nodes.

Authors:  Michael Y Gerner; Wolfgang Kastenmuller; Ina Ifrim; Juraj Kabat; Ronald N Germain
Journal:  Immunity       Date:  2012-08-02       Impact factor: 31.745

8.  MPYS/STING-mediated TNF-α, not type I IFN, is essential for the mucosal adjuvant activity of (3'-5')-cyclic-di-guanosine-monophosphate in vivo.

Authors:  Steven M Blaauboer; Vincent D Gabrielle; Lei Jin
Journal:  J Immunol       Date:  2013-12-04       Impact factor: 5.422

9.  STING-dependent type I IFN production inhibits cell-mediated immunity to Listeria monocytogenes.

Authors:  Kristina A Archer; Juliana Durack; Daniel A Portnoy
Journal:  PLoS Pathog       Date:  2014-01-02       Impact factor: 6.823

Review 10.  Nucleic Acid sensors and type I interferon production in systemic lupus erythematosus.

Authors:  Meena Shrivastav; Timothy B Niewold
Journal:  Front Immunol       Date:  2013-10-07       Impact factor: 7.561

View more
  14 in total

1.  Stimulator of interferon genes agonists attenuate type I diabetes progression in NOD mice.

Authors:  Henrique Lemos; Eslam Mohamed; Lei Huang; Phillip R Chandler; Rong Ou; Rafal Pacholczyk; Andrew L Mellor
Journal:  Immunology       Date:  2019-10-15       Impact factor: 7.397

Review 2.  Taking the STING out of TLR-driven autoimmune diseases: good, bad, or indifferent?

Authors:  Sudesh Pawaria; Shruti Sharma; Rebecca Baum; Kerstin Nündel; Patricia Busto; Ellen M Gravallese; Katherine A Fitzgerald; Ann Marshak-Rothstein
Journal:  J Leukoc Biol       Date:  2016-08-16       Impact factor: 4.962

Review 3.  The STING controlled cytosolic-DNA activated innate immune pathway and microbial disease.

Authors:  Hiroyasu Konno; Glen N Barber
Journal:  Microbes Infect       Date:  2014-10-18       Impact factor: 2.700

Review 4.  The many ways tissue phagocytes respond to dying cells.

Authors:  J Magarian Blander
Journal:  Immunol Rev       Date:  2017-05       Impact factor: 12.988

Review 5.  Therapeutic cancer vaccines.

Authors:  Cornelis J M Melief; Thorbald van Hall; Ramon Arens; Ferry Ossendorp; Sjoerd H van der Burg
Journal:  J Clin Invest       Date:  2015-07-27       Impact factor: 14.808

Review 6.  The host STING pathway at the interface of cancer and immunity.

Authors:  Leticia Corrales; Sarah M McWhirter; Thomas W Dubensky; Thomas F Gajewski
Journal:  J Clin Invest       Date:  2016-07-01       Impact factor: 14.808

Review 7.  Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive 'Cold' Tumors 'Hot'.

Authors:  George C Prendergast; Arpita Mondal; Souvik Dey; Lisa D Laury-Kleintop; Alexander J Muller
Journal:  Trends Cancer       Date:  2017-12-21

Review 8.  Rationale for stimulator of interferon genes-targeted cancer immunotherapy.

Authors:  Thaiz Rivera Vargas; Isis Benoit-Lizon; Lionel Apetoh
Journal:  Eur J Cancer       Date:  2017-02-20       Impact factor: 9.162

Review 9.  Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy.

Authors:  Kyle M Garland; Taylor L Sheehy; John T Wilson
Journal:  Chem Rev       Date:  2022-02-02       Impact factor: 60.622

10.  A STING-activating nanovaccine for cancer immunotherapy.

Authors:  Min Luo; Hua Wang; Zhaohui Wang; Haocheng Cai; Zhigang Lu; Yang Li; Mingjian Du; Gang Huang; Chensu Wang; Xiang Chen; Matthew R Porembka; Jayanthi Lea; Arthur E Frankel; Yang-Xin Fu; Zhijian J Chen; Jinming Gao
Journal:  Nat Nanotechnol       Date:  2017-04-24       Impact factor: 39.213

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.